Skip Navigation

Japanese Journal of Clinical Oncology 2005 35(2):79-83; doi:10.1093/jjco/hyi023
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Takahashi, S.
Right arrow Articles by Kitamura, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takahashi, S.
Right arrow Articles by Kitamura, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2005 Foundation for Promotion of Cancer Research

Combination Chemotherapy of Docetaxel, Ifosfamide and Cisplatin (DIP) in Patients with Metastatic Urothelial Cancer: a Preliminary Report

Satoru Takahashi, Makoto Suzuki, Haruki Kume, Shinya Matsumoto, Naohiko Okamoto, Hiroaki Nishimatsu, Kyoichi Tomita and Tadaichi Kitamura

Department of Urology, Faculty of Medicine, Tokyo University, Tokyo, Japan

For reprints and all correspondence: Satoru Takahashi, Department of Urology, Faculty of Medicine, Tokyo University, 7-3-1, Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail: takahashi-uro{at}h.u-tokyo.ac.jp

Received September 13, 2004; accepted December 20, 2004

Objective: The aim of this study was to evaluate the efficacy and toxicity of a new combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in the treatment of metastatic urothelial cancer.

Methods: Fourteen patients (nine male and five female; aged 59–82 years) with metastatic urothelial carcinoma, including five patients who have a history of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) chemotherapies, received the combination of docetaxel 60 mg/m2 on day 1, and ifosfamide 1.0 g/m2 and cisplatin 20 mg/m2 on days 2–6 and repeated every 21 days, to a maximum of six cycles. Eligibility criteria included performance status (World Health Organization) 0–3; normal bone marrow and liver function; and no symptomatic peripheral neuropathy.

Results: Ten of the 14 patients (72%) demonstrated a partial response (PR), with durations of response ranging from 3 to 12 months [median 6.5 months; 95% confidence interval (CI), 4.1–8.7 months]. The response rate of the five patients with MVAC-refractory cancer was 80% with median duration of response 5.5 months, comparable with that of the cases without previous MVAC therapies. Grade 3–4 granulocytopenia occurred in 10 cases (71%), resulting in three episodes (21%) of febrile neutropenia. Grade 3 thrombocytopenia was observed in five cases (36%). No toxic death was observed. Grade 2 peripheral neuropathy was identified in one case.

Conclusions: This pilot study demonstrated that DIP is an effective regimen for the treatment of metastatic urothelial cancer, and warrants further investigation.

Key Words: docetaxel • ifosfamide • cisplatin • metastatic urothelial cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Jpn J Clin OncolHome page
H. Kume, S. Kakutani, K. Tomita, and T. Kitamura
Salvage Combination Chemotherapy with Docetaxel, Ifosfamide and Cisplatin (DIP): Successful Treatment of a Case with Metastatic Testicular Immature Teratoma
Jpn. J. Clin. Oncol., February 4, 2008; (2008) hym165v1.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.